TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.7 CNY | -0.90% |
|
-4.14% | +3.09% |
Valuation
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,665 | 8,906 | 12,099 | 12,619 | - | - |
| Enterprise Value (EV) 1 | 5,665 | 8,906 | 12,099 | 12,619 | 12,619 | 12,619 |
| P/E ratio | 18.3 x | 24.1 x | 15.1 x | 12.2 x | 10.2 x | 8.39 x |
| Yield | - | - | 1.51% | - | - | - |
| Capitalization / Revenue | 4.51 x | - | 3.86 x | 3.67 x | 3.1 x | 2.61 x |
| EV / Revenue | 4.51 x | - | 3.86 x | 3.67 x | 3.1 x | 2.61 x |
| EV / EBITDA | - | - | 12.5 x | 10.1 x | 8.56 x | 7.16 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 2.32 x | - | 3.62 x | 2.85 x | 2.23 x | 1.76 x |
| Nbr of stocks (in thousands) | 322,319 | 322,319 | 322,319 | 322,319 | - | - |
| Reference price 2 | 17.58 | 27.63 | 37.54 | 38.70 | 38.70 | 38.70 |
| Announcement Date | 3/12/20 | 3/10/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,256 | - | 3,134 | 3,438 | 4,070 | 4,828 |
| EBITDA 1 | - | - | 968.2 | 1,255 | 1,475 | 1,762 |
| EBIT 1 | 351.2 | - | 899.1 | 1,220 | 1,459 | 1,770 |
| Operating Margin | 27.96% | - | 28.69% | 35.49% | 35.85% | 36.66% |
| Earnings before Tax (EBT) 1 | 352.7 | - | 898.2 | 1,220 | 1,459 | 1,770 |
| Net income 1 | 312.3 | 369.8 | 800.9 | 1,025 | 1,226 | 1,487 |
| Net margin | 24.87% | - | 25.55% | 29.81% | 30.12% | 30.8% |
| EPS 2 | 0.9615 | 1.146 | 2.485 | 3.177 | 3.808 | 4.615 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.5669 | - | - | - |
| Announcement Date | 3/12/20 | 3/10/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 13.5% | - | 25% | 23.4% | 21.9% | 21% |
| ROA (Net income/ Total Assets) | - | - | - | 19.6% | 19.2% | 18.7% |
| Assets 1 | - | - | - | 5,230 | 6,385 | 7,952 |
| Book Value Per Share 2 | 7.560 | - | 10.40 | 13.60 | 17.40 | 22.00 |
| Cash Flow per Share 2 | 1.520 | - | 3.300 | 2.880 | 3.720 | 4.330 |
| Capex 1 | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/10/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
38.7
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.09% | 1.72B | |
| +29.28% | 682B | |
| +30.47% | 586B | |
| -3.15% | 364B | |
| +17.54% | 327B | |
| +3.68% | 285B | |
| +16.23% | 240B | |
| +9.98% | 209B | |
| -8.34% | 203B | |
| +7.49% | 165B |
- Stock Market
- Equities
- 600211 Stock
- Financials Tibet Rhodiola Pharmaceutical Holding Co.
